» Articles » PMID: 14610526

Insulin Resistance and Ferritin As Major Determinants of Nonalcoholic Fatty Liver Disease in Apparently Healthy Obese Patients

Overview
Date 2003 Nov 12
PMID 14610526
Citations 35
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: The aims of this study were to test the possible association between nonalcoholic fatty liver disease (NAFLD) and iron and insulin resistance, and to determine the prevalence of NAFLD in apparently healthy obese subjects.

Design: Cross-sectional, clinical epidemiologic study.

Subjects: A total of 210 apparently healthy obese patients, aged from 18 to 65 y, with a body mass index (BMI) of 28 kg/m2 or more, were enrolled in a body weight reduction program in our hospital.

Measurements: All the subjects underwent screening and preprogram examinations, including anthropometric data measurements, biochemistry testing, and ultrasonography of the liver. NAFLD was defined as fatty liver diagnosed by ultrasonography plus persistent elevation of alanine aminotransferase (ALT) levels.

Results: Of the 210 patients, 80% (168/210) had fatty liver. Persistent ALT elevation in two separate tests was further detected in 25.6% (43/168) of patients. Multiple logistic regression analysis showed waist circumference and insulin resistance to be independently associated with fatty liver. Serum ferritin level and insulin resistance were two major risk factors predicting NAFLD.

Conclusion: The prevalence of NAFLD was 20.5% (43/210) in obese patients. As both hyperinsulinemia induced by insulin resistance and iron overload represented by ferritin elevation might damage hepatocytes, we concluded that these two factors were significantly associated with NAFLD in obese patients.\

Citing Articles

Dose-response relationship of serum ferritin and dietary iron intake with metabolic syndrome and non-alcoholic fatty liver disease incidence: a systematic review and meta-analysis.

Yu L, Que T, Zhou Y, Liu Z Front Nutr. 2024; 11:1437681.

PMID: 39410926 PMC: 11476413. DOI: 10.3389/fnut.2024.1437681.


Metabolic Dysfunction-Associated Steatotic Liver Disease Is Associated with Increased Risk of Kidney Cancer: A Nationwide Study.

Oh J, Kim B, Yoon J, Lee H, Park H, Lee J Cancers (Basel). 2024; 16(18).

PMID: 39335133 PMC: 11430135. DOI: 10.3390/cancers16183161.


Prevalence, characteristics, and risk factors of non-alcoholic fatty liver disease in North East of Iran: a population-based study.

AkbariRad M, Pezeshki Rad M, Nobakht H, Moodi Ghalibaf A, Firoozi A, Torshizian A BMC Gastroenterol. 2024; 24(1):212.

PMID: 38926664 PMC: 11210030. DOI: 10.1186/s12876-024-03302-y.


Associations between serum ferritin baselines and trajectories and the incidence of metabolic dysfunction-associated steatotic liver disease: a prospective cohort study.

Song Z, Miao X, Xie X, Tang G, Deng J, Hu M Lipids Health Dis. 2024; 23(1):141.

PMID: 38760825 PMC: 11100236. DOI: 10.1186/s12944-024-02129-6.


Gender-Based Association of Coronary Artery Calcification and Framingham Risk Score With Non-alcoholic Fatty Liver Disease and Abdominal Obesity in Taiwanese Adults, a Cross-Sectional Study.

Tsou M, Chen J Front Cardiovasc Med. 2022; 9:803967.

PMID: 35310993 PMC: 8928543. DOI: 10.3389/fcvm.2022.803967.